Cytochrome P450 in neurological disease

被引:44
|
作者
Liu, M
Hurn, PD
Alkayed, NJ
机构
[1] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97239 USA
[2] Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21287 USA
关键词
cytochrome P450; eicosanoids; EETs; neurosteroids; estrogen; cerebral ischemia; preconditioning; neuroprotection;
D O I
10.2174/1389200043335540
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Advances in a multitude of disciplines support in emerging role for cytochrome P450 enzymes and their metabolic substrates and end-products in the pathogenesis and treatment of central nervous system disorders. including acute cerebrovascular injury. such as stroke, chronic neurodegenerative disease. Such as Alzheimer's and Parkinson's disease. as well as epilepsy. Multiple sclerosis and psychiatric disorders, including anxiety and depression. The neural tissue contains its own unique set of P450 genes that are regulated in a manner that is distinct from their molecular regulation in peripheral tissue. furthermore. brain P450s catalyze the formation of important brain signaling such as neurosteroids and eicosanoids, and metabolize substrates as diverse as vitamins A and D, cholesterol, bile acids, as well as centrally acting drugs, anesthetics and environmental neurotoxins. These unique characteristics allow this Family of proteins and their metabolites to perform such vital functions in brain as neurotrophic support, neuroprotection control of cerebral blood flow, temperature control, neuropeptide release, maintenance of brain cholesterol homeostasis. elimination of retinoids from CNS, regulation of neurotransmitter levels and other functions important in brain physiology, development and disease.
引用
收藏
页码:225 / 234
页数:10
相关论文
共 50 条
  • [1] Measurement of cytochrome P450 and NADPH–cytochrome P450 reductase
    F Peter Guengerich
    Martha V Martin
    Christal D Sohl
    Qian Cheng
    [J]. Nature Protocols, 2009, 4 : 1245 - 1251
  • [2] Cytochrome p450 enzymes and cardiovascular disease
    Hunter, AL
    Cruz, RP
    Cheyne, BM
    McManus, BM
    Granville, DJ
    [J]. CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2004, 82 (12) : 1053 - 1060
  • [3] Cytochrome P450
    P. H. Roos
    N. Jakubowski
    [J]. Analytical and Bioanalytical Chemistry, 2008, 392 : 1015 - 1017
  • [4] Cytochrome P450
    Roos, P. H.
    Jakubowski, N.
    [J]. ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 2008, 392 (06) : 1015 - 1017
  • [5] Cytochrome P450
    Poulos, TL
    [J]. CURRENT OPINION IN STRUCTURAL BIOLOGY, 1995, 5 (06) : 767 - 774
  • [6] Cytochrome p450 recognition sites for NADPH cytochrome p450 reductase
    Dai, R
    Robinson, RC
    Friedman, FK
    [J]. BIOPHYSICAL JOURNAL, 1996, 70 (02) : SU162 - SU162
  • [7] Measurement of cytochrome P450 and NADPH-cytochrome P450 reductase
    Guengerich, F. Peter
    Martin, Martha V.
    Sohl, Christal D.
    Cheng, Qian
    [J]. NATURE PROTOCOLS, 2009, 4 (09) : 1245 - 1251
  • [8] Human Cytochrome P450 Interactions with Redox Partner Cytochrome P450 Reductase
    Burris-Hiday, Sarah
    Chai, Mengqi
    Gross, Michael L.
    Scott, Emily
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2023, 385
  • [9] Membrane Anchor of Cytochrome P450 Reductase Suppresses the Uncoupling of Cytochrome P450
    Miyamoto, Masayoshi
    Yamashita, Taku
    Yasuhara, Yuki
    Hayasaki, Akinori
    Hosokawa, Yukari
    Tsujino, Hirofumi
    Uno, Tadayuki
    [J]. CHEMICAL & PHARMACEUTICAL BULLETIN, 2015, 63 (04) : 286 - 294
  • [10] Hepatic cytochrome P450 regulation in disease states
    Cheng, PY
    Morgan, ET
    [J]. CURRENT DRUG METABOLISM, 2001, 2 (02) : 165 - 183